Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.

about

Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

P2860

Q48825054-46DB002C-454A-4EB2-AA01-FC08BD55FDDC

P2860

Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.

Item

http://www.wikidata.org/entity/Q38757680

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.

@en

type

Item

label

Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.

@en

prefLabel

Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.

@en

P1476

Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.

@en

P2093

Anton I Vinkov

http://www.w3.org/2001/XMLSchema#string

Lyubomir A Dourmishev

http://www.w3.org/2001/XMLSchema#string

Maria H Hristova

http://www.w3.org/2001/XMLSchema#string

Zornitsa G Kamenarska

http://www.w3.org/2001/XMLSchema#string

P2860

Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction.

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Epratuzumab in the therapy of oncological and immunological diseases.

First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus.

Etanercept in refractory lupus arthritis: An observational study.

Golimumab-exacerbated subacute cutaneous lupus erythematosus.

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

P304

89-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1515/FOLMED-2015-0025

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

294509340

http://www.w3.org/2001/XMLSchema#string

P698

26933777

http://www.w3.org/2001/XMLSchema#string

Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.

about

P2860

P2860

Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698